Report
Gregory Ramirez

SAP Q3 2018 call feedback: replaying the same song…

BUY | EUR115 vs114
Cloud subscription is almost no longer an option for SAP clients
Revenue mix remains a key parameter for operating margin
SAP is still on track on migrations to S/4HANA
We raise our Fair Value to EUR115 from EUR114
Underlyings
Resapp Health

ResApp Health is engaged in developing, manufacturing and marketing health related diagnostics and developing Co.'s intellectual property. Through its subsidiary, Co. is engaged in manufacturing and selling test kit for monitoring HIV viral load and the response of HIV infection to drug therapies (HIV viral load assays and HIV drug resistance assays).

SAP SE

SAP is engaged in selling licenses for software solutions and related support services. Co. derives its revenue from fees charged to its customers for the use of its cloud solutions and for licensing of on-premise software products and solutions. Additional sources of revenue are support, professional services, development, training, and other services. Co. has more than 300,000 customers in over 180 countries. Co.'s SAP HANA platform holds the ability to simplify both the user experience and the overall IT landscape, creating a smaller data footprint, increased system throughput, and easier data processing and operation.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Gregory Ramirez

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch